This information may be useful in considering simple, low-toxicity combinations to reduced progression of cardiometabolic disease, including in patients with previous liver disease, liver injury, or mutations in the ApoE gene diminishing their response to statins (5, 53, 54). This evidence concerns the gene APOE and liver disorder.